AZ1495(compound28)是具有口服活性的，白介素-1受体相关激酶4(IRAK4)的抑制剂，其对IRAK4和IRAK1的IC50值分别为5nM和23nM。具有治疗突变型MYD88L265P弥漫性B细胞淋巴瘤(DLBCL)的活性。
CAS：2196204-23-4
分子式：C21H31N5O2
分子量：385.5
纯度：98%
存储：Store at -20°C

Background:

AZ1495 (compound 28) is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL)[1].

[1]. Scott JS, et al. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma. J Med Chem. 2017 Dec 28;60(24):10071-10091.